Skip to content
Many thanks to Dr. John Barry for his commentary and sharing of these take-aways from the sessions at the 2025 meeting Napa.
- The number of attendees was surprising for a non-Hawaii meeting.
- The TAR-20 pretzel concept of delivering chemotherapy into the bladder is an interesting one; will it be combined with the double-J ureteral stent concept for the delivery of therapeutic agents to treat upper tract urothelial carcinomas?
- Many of the one-slide presenters for the 2-minute poster presentations can’t count.
- Intravesical gemcitabine is an affordable treatment for high-risk, non-muscle invasive bladder cancer.
- Re-induction with Nadofaragene Firadenovec is safe.
- Preoperative biomarker scores [neutrophil/lymphocyte (NLR) and/or hemoglobin, serum albumin, lymphocyte, platelet (HALP)] can be outcome predictors for radical cystectomy patients.
- Sub-centimeter pulmonary nodules have no influence on outcomes in clinical stage 1 non-seminoma testis tumor patients.
- Fluconazole should probably be added to penile prosthesis perioperative antibiotic protocols.
- Optilume works best when it’s the first treatment for urethral strictures.
- A single Zwitterionic coating reduced ureteral stent encrustation – in a lab model.
- Endourologists are three times more likely than general urologists to treat symptomatic stones at initial presentations.
- When AI doesn’t know an answer, it may hallucinate.
- The Charlson Comorbidity Index is a weighted system, not a simple counting of comorbidities.
- Darolutamide, an androgen receptor inhibitor (ARI), was the star of many prostate cancer presentations.
- Health policy forums tend to run overtime.
- The “peak” and the “end” are what one remembers about an experience.
- When given a podium and a microphone, lawyers, like oncologists, seem to lose track of time.
- As high-resolution micro-ultrasound develops, will it replace MRI for prostate cancer staging, biopsy targeting, and focal therapy?
- Is whole gland treatment of prostate cancer overtreatment? Focal therapists seek to answer the question.
- Will urine-based tumor markers, like MyProstate Score 2.0, make prostate cancer screening more likely to be done by primary care practitioners?
- Will urine-based tumor markers, like Cxbladder, become substitutes for cystoscopy and cytology to screen for urothelial cancer and to monitor responses to therapy?
- Check the retail drug costs for a health care system rather than costs for an individual patient.
- Beta-3 agonists are becoming preferred over anticholinergics for over-active bladder treatment. A problem for patients is the financial gauntlet.
- Asymptomatic bacteriuria doesn’t need to be treated, even in transplant recipients.
- The Bubble Access Needle is a clever adjunct for percutaneous access to a kidney.
- Topical vaginal estrogen is safe for women with hormone-sensitive cancers.
- Machine learning algorithms are useful to predict survival of prostate cancer patients.
- The concept of a urachus-based peritoneal hinge-flap for bladder augmentation is clever.
- “MiGUTS” is a clever acronym; it stands for “Multi-Institutional Genitourinary Trauma Study.”
- Should there be an AUA course entitled “Transition of Care for Pediatric Spina Bifida Patients to Adult Urology?” (There is, it was just announced.).
- Screen for depression and suicidal thoughts in young men with testis cancer.
- The GU Tumor Board was great as were the State-of-the-Art Lectures and Expert Panels.
- Dr. Boorjian gave an excellent Sadoughi Lecture.
- Passing a double-J stent in a case of ureteral obstruction due to invasive bladder cancer carries with it the risk of cancer seeding of the upper urinary tract.
- It’s OK to biopsy small renal masses. Many of them don’t need to be treated.
- A thulium laser will cut a stone-encased ureteral stent. A holmium laser is less likely to do so.
- Don’t do laser lithotripsy in an air bubble.
- Congratulations to Joel Gelman, the WSAUA Distinguished Member for 2025.
- The Round Table was great fun. Vampires, Captain Hook, Peter Pan, and the Big Leballski were all featured.
- Hawaii, here we come.
Scroll To Top